The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin.
Patients reported barriers to care including social determinants of health in obesity management by their healthcare provider.
In indeterminate thyroid nodules, evidence of thick post-microcystic reflection on ultrasound was found to be associated with malignant nodules.
Hypothyroidism is a risk factor for increased length of hospital stay and mortality in patients with congestive heart failure.
Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease.
A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population.
Although hypothyroidism is linked to depression, anxiety is the main complaint of euthyroid patients with thyroid disease, with or without Hashimoto thyroiditis.
Biochemical markers and clinical signs and symptoms of endogenous Cushing syndrome improved after 6 months of levoketoconazole therapy.
The use of insulin pump to deliver continuous pulsatile cortisol may be a viable treatment option in patients with severe adrenal insufficiency who are unresponsive to oral corticosteroids.
Treatment with linagliptin in patients with type 2 diabetes and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events.
Abaloparatide followed by alendronate treatment may improve bone mineral density in women with postmenopausal osteoporosis and type 2 diabetes.
Type 2 diabetes is associated with increased risk for fractures in the short term but not in the long term.